Research at the Khiabanian Lab

Ultra-deep sequencing of cancer

Top: Sensitivity for discovering unknown mutations vs. backtracking known mutations with ultra-deep sequencing. Bottom: The rise of small TP53 mutated subclones after treatment; only single-cell analysis can elucidate whether all mutations belong to the same clone.

Therapeutic failure in cancer is often associated with tumor heterogeneity and the natural selection of resistant clones, a mechanism shared by blood and solid malignancies. Recent studies strongly suggest that limiting the knowledge of tumor genetics to the dominant clone may be uninformative for an accurate prediction of outcome and optimal therapeutic decision; therefore, it is imperative to capture the distribution of mutants and the extent of genomic diversity in tumor sub-population structure. The goal of our lab, at Center for Systems and Computational Biology, is to identify markers of selection, study the impact of treatment strategies on tumor molecular history and time the rise of resistance in cancer.

High-throughput genomics techniques facilitate rapid sequencing of patients and provide estimates of allele frequencies at each position, albeit with greater error and shorter reads than traditional sequencing methods. We have developed robust algorithms that model the background noise and establish depth thresholds to distinguish true variants from errors. We have applied these methodologies to investigate emerging infectious disease outbreaks, intra-host pathogen evolution, and unregulated cell growth in cancer.

Our work has helped elucidating the mutational landscape of human neoplasms and the role of subclonal variants in disease transformation and relapse. In particular, the application of ultra-deep sequencing and statistical analysis to more than 300 newly diagnosed cases of chronic lymphocytic leukemia (CLL), the most common leukemia in adults, identified small mutations in the TP53, NOTCH1, SF3B1, and BIRC3 genes, four often-mutated drivers of this neoplasm. These mutations, present in 2 out of 1,000 wild type alleles, were missed by traditional Sanger sequencing. These TP53 mutated subclones identified before treatment became the predominant population at the time of disease relapse, and patients harboring them showed the same clinical phenotype and poor survival as patients carrying clonal TP53 lesions.

Evolutionary patterns in cancer progression can be described through two models of growth. In linear evolution, genetic lesions of the dominant clone from an earlier phase are present in later phases. In contrast, dominant clones in branched evolution share only partial genetic alterations in different phases. Selective pressures can spur tumor evolution and change its mode of progression from linear to branched.

Molecular history of dominant clones in ALL from diagnosis to relapse as represented by phylogenetic trees; projection of these trees, shown as circles scaled by total number of mutations, indicate branched clonal evolution as the central mechanisms of disease progression.

Cancer’s often-branched evolutionary process suggests that different approaches may be needed to evaluate and treat multiple aspects of disease. We have reported genomic evidence for branched evolution in disease transformation of CLL and follicular lymphoma to more aggressive malignancies. More recently, we investigated the clonal evolution of acute lymphoblastic leukemia (ALL), the most common neoplasm in children, from its initial diagnosis to relapse. Current therapy for ALL results in clinical and hematologic remission in over 90% of cases; however, despite intensive chemotherapy, 20% of pediatric patients and over 50% of adult patients with ALL do not achieve complete remission or relapse after intensified chemotherapy. Our whole-exome and whole-genome sequencing analyses showed that relapsed ALL originates primarily by branched evolution from ancestral subclones that are related to but are distinct from the leukemic population at diagnosis. In particular, we identified relapse-specific mutations in the NT5C2, KRAS, and NRAS genes, which we have shown to induce resistance to therapeutic regimens.

In addition to studying the underlying genetics of cancer, we are interested in investigating the contribution of foreign pathogens and host microbiome to disease development and treatment response. To this end, we are extensively collaborating with physicians and scientists at Rutgers and other institutions in the New York metropolitan area.

Lab Leadership

Dr. Hossein Khiabanian

Dr. Hossein Khiabanian is an Assistant Professor of Pathology in the Division of Medical Informatics. He trained in physics and observational cosmology at Brown University, and prior to joining Rutgers, was a member of the faculty in Departments of Systems Biology and Biomedical Informatics at Columbia University. To learn more about our lab, and employment and collaborative opportunities, please visit

Relevant Publications

  • Oshima K. , Khiabanian H. , et al. Mutational landscape, clonal evolution patterns and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences 2016. PMID:27655895
  • Zairis S., Khiabanian H., Blumberg A., Rabadan R. Genomic data analysis in tree spaces. arXiv:1607.07503 2016. arXiv
  • Spina V. , Khiabanian H. , et al. The Genetics of Nodal Marginal Zone Lymphoma. Blood 2016. PMID:27335277
  • Rasi S. , Khiabanian H. , et al. Clinical impact of small subclones harboring NOTCH1, SF3B1, or BIRC3 mutations in chronic lymphocytic leukemia. Haematologica 2016. PMID:26819056
  • Almeida da Silva A. , Abate F. , Khiabanian H., et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nature Genetics 2015. PMID:26551667
  • Emmett K., Lee A., Khiabanian H. , Rabadan R. High-resolution genomic surveillance of 2014 ebolavirus using shared subclonal variants. PLoS Currents 2015. PMID:25737802
  • Rossi D. , Khiabanian H. , et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014. PMID:24501221
  • Palomero T. , Couronné L. , Khiabanian, H. , et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nature Genetics 2014. PMID:24413734
  • Wang J. , Khiabanian H. , Rossi D. , et al. Tumor Evolutionary Directed Graphs and the History of Chronic Lymphocytic Leukemia. eLife 2014. PMID:25496728
  • Khiabanian H. , et al. Viral diversity and clonal evolution from unphased genomic data. BMC Genomics 2014. PMID:25573168
  • Zairis S., Khiabanian H., Blumberg A., Rabadan R. Moduli spaces of phylogenetic trees describing tumor evolutionary patterns. Lecture Notes in Computer Science Volume 8609 2014. Springer
  • Pasqualucci L., Khiabanian H., et al. Genetics of follicular lymphoma transformation. Cell Reports 2014. PMID:24388756
  • Fabbri G. , Khiabanian H. , et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. The Journal of Experimental Medicine 2013. PMID:24127483
  • Tzoneva G. , Perez Garcia A. , Carpenter Z. , Khiabanian H., et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Medicine 2013. PMID:23377281
  • Dapito D.H., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012. PMID:22516259
  • Van Vlierberghe P. , Palomero T. , Khiabanian H., et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nature Genetics 2010. PMID:20228800
  • Trifonov V., Khiabanian H., Rabadan R. Geographic Dependence, Surveillance and the Origins of the 2009 Influenza A (H1N1) Virus. The New England Journal of Medicine 2009. PMID:19474418

effective 3/6/17




precision medicine at Rutgers Cancer Institute




Donate Now








Proud member of
Big Ten Cancer Research Consortium



Rutgers Health